Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.

Ali Akbar U, Mondal A, Vorla M, Alruwaili W, Lacoste J, Thyagaturu H, Shafique N, Shakeel S, Taha A, Balla S

The American journal of cardiology6 May 2026Cited by 1 (Europe PMC)

PMID42103200DOI10.1016/j.amjcard.2026.05.004PepBankPUB-42103200

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including dulaglutide were linked to lower mortality than non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including dulaglutide were linked to fewer deaths than non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAll-cause mortality
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Mortality · Whole body
Measurements
Hazard ratio
0.68
pooled GLP-1 receptor agonists
Source sentences
Summary
GLP-1 RA use was associated with lower all-cause mortality (hazard ratio [HR] 0.68; 95% CI 0.53 to 0.88; p = 0.003)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4210320001
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including liraglutide were linked to lower mortality than non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including liraglutide were linked to fewer deaths than non-use.
Peptide
Liraglutide
Outcome
DecreaseAll-cause mortality
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Mortality · Whole body
Measurements
Hazard ratio
0.68
pooled GLP-1 receptor agonists
Source sentences
Summary
GLP-1 RA use was associated with lower all-cause mortality (hazard ratio [HR] 0.68; 95% CI 0.53 to 0.88; p = 0.003)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4210320002
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including semaglutide were linked to lower mortality than non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including semaglutide were linked to fewer deaths than non-use.
Peptide
Semaglutide
Outcome
DecreaseAll-cause mortality
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Mortality · Whole body
Measurements
Hazard ratio
0.68
pooled GLP-1 receptor agonists
Source sentences
Summary
GLP-1 RA use was associated with lower all-cause mortality (hazard ratio [HR] 0.68; 95% CI 0.53 to 0.88; p = 0.003)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4210320003
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including dulaglutide were linked to fewer myocardial infarctions than non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including dulaglutide were linked to fewer heart attacks than non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAcute myocardial infarction
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Subdistribution hazard ratio
0.63
pooled GLP-1 receptor agonists
Source sentences
Summary
acute myocardial infarction (subdistribution HR [sHR] 0.63; 95% CI 0.41 to 0.98; p = 0.040)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4210320004
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including liraglutide were linked to fewer myocardial infarctions than non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including liraglutide were linked to fewer heart attacks than non-use.
Peptide
Liraglutide
Outcome
DecreaseAcute myocardial infarction
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Subdistribution hazard ratio
0.63
pooled GLP-1 receptor agonists
Source sentences
Summary
acute myocardial infarction (subdistribution HR [sHR] 0.63; 95% CI 0.41 to 0.98; p = 0.040)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4210320005
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including semaglutide were linked to fewer myocardial infarctions than non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including semaglutide were linked to fewer heart attacks than non-use.
Peptide
Semaglutide
Outcome
DecreaseAcute myocardial infarction
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Subdistribution hazard ratio
0.63
pooled GLP-1 receptor agonists
Source sentences
Summary
acute myocardial infarction (subdistribution HR [sHR] 0.63; 95% CI 0.41 to 0.98; p = 0.040)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4210320006
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including dulaglutide were linked to fewer heart failure hospitalizations than non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including dulaglutide were linked to fewer heart failure admissions than non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHeart failure hospitalization
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Subdistribution hazard ratio
0.61
pooled GLP-1 receptor agonists
Source sentences
Summary
and heart failure hospitalization (sHR 0.61; 95% CI 0.39 to 0.95; p = 0.028)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4210320007
08HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including liraglutide were linked to fewer heart failure hospitalizations than non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including liraglutide were linked to fewer heart failure admissions than non-use.
Peptide
Liraglutide
Outcome
DecreaseHeart failure hospitalization
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Subdistribution hazard ratio
0.61
pooled GLP-1 receptor agonists
Source sentences
Summary
and heart failure hospitalization (sHR 0.61; 95% CI 0.39 to 0.95; p = 0.028)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4210320008
09HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including semaglutide were linked to fewer heart failure hospitalizations than non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including semaglutide were linked to fewer heart failure admissions than non-use.
Peptide
Semaglutide
Outcome
DecreaseHeart failure hospitalization
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Subdistribution hazard ratio
0.61
pooled GLP-1 receptor agonists
Source sentences
Summary
and heart failure hospitalization (sHR 0.61; 95% CI 0.39 to 0.95; p = 0.028)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4210320009
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including dulaglutide showed no significant stroke association versus non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including dulaglutide showed no significant stroke link versus non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeStroke
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Subdistribution hazard ratio
0.76
pooled GLP-1 receptor agonists
Source sentences
Summary
no significant association was observed for stroke (sHR 0.76; 95% CI 0.52 to 1.10; p = 0.146).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4210320010
11HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including liraglutide showed no significant stroke association versus non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including liraglutide showed no significant stroke link versus non-use.
Peptide
Liraglutide
Outcome
No significant changeStroke
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Subdistribution hazard ratio
0.76
pooled GLP-1 receptor agonists
Source sentences
Summary
no significant association was observed for stroke (sHR 0.76; 95% CI 0.52 to 1.10; p = 0.146).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4210320011
12HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with ASCVD and excess weight without diabetes, pooled GLP-1 drugs including semaglutide showed no significant stroke association versus non-use.
In plain wordsIn adults with cardiovascular disease and excess weight without diabetes, pooled medicines including semaglutide showed no significant stroke link versus non-use.
Peptide
Semaglutide
Outcome
No significant changeStroke
Study
n = 14,844
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Subdistribution hazard ratio
0.76
pooled GLP-1 receptor agonists
Source sentences
Summary
no significant association was observed for stroke (sHR 0.76; 95% CI 0.52 to 1.10; p = 0.146).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010, to December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes.
Summary · context
New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4210320012

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.

Summary

Results from this study12

Studies that did not test the peptide alone12

Version history

Subjects

Publication types

MeSH terms

Keywords